China Yongda Automobiles Services

Upgrade on valuation

Why now? Weak car supply reinforces our view on easing inventory pressure

Global Research

Our channel checks suggest BMW has agreed a 2015 sales target of 490,000 units with dealers, up 15% YoY, and in line with our expectation of a low- to mid-teens increase. Meanwhile, car imports remain weak YTD according to recent government statistics. We reiterate our view that dealers will face less inventory pressure in 2015, and that new car sales margins will stabilize. Meanwhile, we believe BMW dealers had already received the 2014 rebates by late February 2015. We believe most of these rebates will be booked in H214, but the timing gives the dealers some leeway in more flexible allocation

Market too bearish on regulation reform; limited impact from parallel import

The regulators have not announced the reforms to the franchise law, which we attribute to strong opposition and lobbying by the OEMs. We believe the potential benefits to dealers have not been fully appreciated by the capital market. We still expect a finalized version to be released within 2015. Meanwhile, parallel imports were officially launched in the Shanghai Free Trade Zone in February 2015, and Yongda was one of qualified dealers. We expect minimal impact to its existing margins and ASP.

Earning revisions due to higher expenses and finance cost assumptions

We lower our H214 earnings forecast by 14% due to a lower-than-expected sales margin for new luxury cars, higher finance costs and operating expenses from new business initiatives in H214. We also lower our 2015/16E earnings slightly, 6.6%/6.9%, mainly to reflect the slightly lower sales margin for new luxury cars and our higher finance cost assumptions. We forecast 2014/15/16 fully-diluted EPS of Rmb0.41/Rmb0.49/Rmb0.62. Our earnings estimate is 4%/12%/12% lower than consensus 2014/15/16.

Valuation: upgrade from Neutral to Buy on lagging performance

Yongda's share price has dropped 17% YTD, lagging its peers' (Baoxin 8%; Zhentong: 14%; HSCEI -5%). Despite lower forecasts, we see this as an attractive entry point, and upgrade Yongda from Neutral to Buy. We derive our HK\$6.50 price target (previously HK\$7.30) from a DCF-based methodology and explicitly forecast long-term valuation drivers using UBS's VCAM tool (WACC: 9.5%), and implies 10.5x 2015E fully-diluted PE. The stock is currently trading at 6.9x fully-diluted 2015E PE, and 1.1x 2015E P/BV.

Equities

China Retailers, Specialty

12-month rating	Buy
	Prior: Neutral
12m price target	HK\$6.50
	Prior: HK\$7.30
Price	HK\$4.22

RIC: 3669.HK BBG: 3669 HK

Trading data and key metrics

52-wk range	HK\$7.	45-4.21
Market cap.	HK\$6.25bn/US	\$0.80bn
Shares o/s	1,480	m (ORD)
Free float		18%
Avg. daily volume ('0	00)	385
Avg. daily value (m)		HK\$1.8
Common s/h equity (12/14E) Rm	b3.88bn
P/BV (12/14E)		1.3x
Net debt / EBITDA (12	2/14E)	2.3x

EPS (UBS, diluted) (Rmb)

	From	То	% ch	Cons.
12/14E	0.46	0.41	-9.70	0.45
12/15E	0.53	0.49	-6.65	0.59
12/16E	0.67	0.62	-6.86	0.75

Ming Xu Analyst

ming.xu@ubs.com +852-3712 3680

Yankun Hou

Analyst yankun.hou@ubs.com +852-3712 4451

Mark Leung

Associate Analyst mark.leung@ubs.com +852-2971 8636

Highlights (Rmbm)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Revenues	20,304	21,712	26,097	30,481	34,690	38,829	42,712	46,983
EBIT (UBS)	911	893	1,064	1,255	1,510	1,814	2,194	2,517
Net earnings (UBS)	505	470	588	646	807	1,021	1,252	1,441
EPS (UBS, diluted) (Rmb)	0.34	0.32	0.40	0.41	0.49	0.62	0.76	0.88
DPS (Rmb)	0.28	0.10	0.12	0.13	0.16	0.21	0.25	0.29
Net (debt) / cash	(1,296)	(1,727)	(3,670)	(3,748)	(4,207)	(4,585)	(4,646)	(5,263)
Profitability/valuation	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
EBIT margin %	4.5	4.1	4.1	4.1	4.4	4.7	5.1	5.4
ROIC (EBIT) %	35.0	22.5	17.5	16.8	18.1	19.1	20.7	20.9
EV/EBITDA (core) x	-	8.8	7.7	3.7	3.1	2.6	2.2	3.3
P/E (UBS, diluted) x	-	17.9	15.2	8.1	6.9	5.5	4.5	3.9
Equity FCF (UBS) yield %	-	(7.1)	(12.4)	10.4	4.9	8.5	15.8	7.0
Net dividend yield %	-	1.7	2.0	3.9	4.8	6.1	7.5	8.6

Source: Company accounts, Thomson Reuters, UBS estimates. Metrics marked as (UBS) have had analyst adjustments applied. Valuations: based on an average share price that year, (E): based on a share price of HK\$4.22 on 12 Mar 2015 22:39 HKT

www.ubs.com/investmentresearch

This report has been prepared by UBS Securities Asia Limited. ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 13. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Investment Thesis Yongda Automobiles

Investment case

Yongda has high exposure to eastern China, where demand for luxury cars has been persistently strong (nearly 40% of national sales for the past six years), and there is a large ownership base. We believe the company's commitment to building its own brand will lead to profitable cross-selling opportunities in aftersales services. Yongda has made significant improvement in its expense coverage, due mainly to a rising service gross margin, which we believe will help improve profit margins and earnings stability. However, Yongda's new car sales margin remains below those of peers, and we attribute this to slow progress in cost cutting and aggressive network expansion. The rising service gross margin is offset by a lower new car sales margin than those of peers. Our earnings estimates and price target are below consensus after we factor in the short-term negative impact from the anti-trust investigation.

Upside scenario

Yongda's earnings are driven mainly by luxury car sales. In our base case, we forecast its luxury car sales gross margins will reach 4.4% in 2015. If Yongda's luxury car sales gross margin reaches 4.8% in 2015 due to an expanding base of middle-income earners and a stronger-than-expected increase in replacement demand, and assuming a 10.5x 2015 PE, the valuation in our upside scenario will be HK\$7.10/share.

Downside scenario

Our downside scenario assumes a further drop in the luxury car sales gross margin due to a worse-than-expected impact from the industry's reformation. If Yongda's gross margin from luxury sales falls to 4.0% in 2015, and assuming a 10.5x 2015 PE, the valuation in our downside scenario will be HK\$6.01/share.

Upcoming catalysts

Positive: The ramp-up of its used-car trading JV with BitAuto and Youxinpai.

12-month rating

Buy

12m price target

HK\$6.50


Business description

China Yongda Automobiles Services Holdings is a vehicle retailer and comprehensive service provider in China focused on luxury and ultra-luxury brands. Its portfolio of luxury and ultra-luxury brands includes BMW, Porsche, Jaguar, Land Rover, Infiniti, Cadillac and Volvo. In addition, the company operates 4S dealerships for a select portfolio of mid-range to high-end brands, including Buick, Chevrolet, Volkswagen, Toyota, Honda and Nissan.

Industry outlook


We expect premium cars to remain one of the best-performing segments and to continue gaining market share. In the long term, we expect demand for luxury and ultra-luxury cars to be driven by rising wealth as a result of continued economic growth, demand for upgrades from mid-range to high-end cars, and a low penetration rate. As car ownership increases, growth of the services and derivative businesses should also be strong.

Revenues by segment



Source: Company data, UBS estimates

Sales volume breakdown



Source: Company data, UBS estimates

Valuations and share price derivation

We upgrade Yongda from a Neutral to a Buy rating on its lagging share price performance. Since the beginning of 2015, Zhengtong and Baoxin have outperformed the HSCEI by 19% and 13%, respectively, while Yongda has underperformed by 12%. We believe its current valuation is attractive and provides an adequate safety margin.

25% 20% 15% 10% 0% -5% -10% -15% -20% -25%

1-Feb-1 3-Feb-1 5-Feb-15

Baoxin relative performance

Zhongsheng relative performance

1-Feb-15

9-Feb-1

13-Feb-1 15-Feb-1

Figure 1: 2015 YTD Relative performance between Hang Seng China Enterprises Index (HSCEI) and China auto dealers

Source: Bloomberg

We derive our price target from a DCF-based methodology and explicitly forecast long-term valuation drivers using UBS's VCAM tool. We assume a WACC of 9.5%. Our price target implies 10.5x fully diluted 2015E PE. We decrease our mid-term and long-term EBIT margin assumption by 0.2% each to reflect intensifying industry competition and higher operational costs from the company's new business operations. Our price target implies a 10.5x 2015E PE.

22-Jan-15

20-Jan-1

24-Jan-15

Jan-15 30-Jan-15

8

Jan-1

16-Jan-15

14-Jan-1

18-Jan-15

12-Jan-15

HSCEI relative performance

Yongda relative performance

10-Jan-15

The stock currently trades at a fully-diluted 2015E PE of 6.9x, and 1.1x 2015E PB.

We have Buy rating on all four dealers we cover. In descending order, we like Baoxin, Zhengtong, Zhongsheng and Yongda. We continue to prefer Baoxin thanks to its improving BMW operations and its e-commerce business. Zhengtong has outperformed the others YTD, but we believe the official launch of its auto finance operations will continue to support its share price. We attribute Zhongsheng's weakness YTD mainly to 1) concerns about its weak H214 results, 2) margin risks from price cuts to Mercedes after-sales service charges; 3) its conservatism on new businesses. Despite these concerns, we believe its current valuation looks attractive. We like Yongda for its operations, but liquidity may cap upside to its share price.

We also note that the H-share dealership companies look much cheaper than their peers in A shares, as shown below. We believe they may benefit from the southbound flow of Mutual Market Access (MMA) investment money. Currently Baoxin, Zhengtong and Zhongsheng are MMA-qualified stocks.

In the dealership space, we like Baoxin, Zhengtong, Zhongsheng, and Yongda, in that order

23-Feb-15

25-Feb-1 27-Feb-1

Zhengtong relative performance

21-Feb-1


17-Feb-15

Figure 2: Valuation compsheet

		Market Cap	EPS CAGR	P.	/E (dilute	d)		P/BV		E	V/EBITDA	,	i	ROE (%)	Divide	end yiel	d (%)
Code		(in US\$ m)	(13-16E)	2014E	2015E	2016E	14E	15E	16E	2014E	2015E	2016E	14E	15E	16E	14E	15E	16E
HK1293	Baoxin	1,601	20%	8.6	7.3	5.8	1.7	1.4	1.1	6.2	5.2	4.1	21.9	21.2	21.4	0.0	0.0	0.0
HK1728	Zhengtong	1,117	18%	7.2	6.0	5.1	0.8	0.7	0.6	4.8	3.6	2.8	12.0	13.0	13.3	0.0	0.0	0.0
HK0881	Zhongsheng	1,347	14%	7.1	6.7	5.7	0.7	0.6	0.6	4.7	4.4	4.0	11.0	9.7	10.6	2.2	3.0	4.3
HK3669	Yongda	803	16%	8.2	6.9	5.5	1.3	1.1	1.0	3.7	3.1	2.6	17.7	19.4	21.3	3.9	4.8	6.1
601258.SS	Pang Da	3,968	80%	109.6	29.5	16.5	NA	NA	NA	NA	NA	NA	2.2	4.9	9.4	NA	NA	NA
600335.SS	Sinomach	2,196	16%	16.2	13.0	11.5	2.6	2.2	1.8	NA	NA	NA	16.3	17.3	17.0	0.9	1.1	1.4
HK1114	Brilliance	9,503	30%	10.7	9.5	8.1	3.3	2.6	2.1	-858.9	501.2	174.3	35.9	31.3	28.6	1.7	2.6	3.1


Source: Bloomberg, UBS estimates

Figure 3: 12-month forward PE band



Note: Based on 12-month forward consensus. Source: Datastream, IBES

Figure 4: 12-month forward P/BV band




Note: Based on 12-month forward consensus. Source: Datastream, IBES

Weakening car import, and BMW's modest sales target

Our channel checks suggest BMW has just agreed a 2015 sales target of 490,000 units with dealers, up 15% YoY, which is in line with our expectation of low- to mid-teens percentage growth, but is the lowest sales growth target over the past four to five years. On top of the modest growth target, BMW's head of global sales promised the dealers a quarterly sales target review based on market development.


We reiterate our view that dealers will face less inventory pressure in 2015, while new car sales margins will stabilize. In addition, the one-time special rebate of Rmb5bn from BMW China had already been distributed to the dealers at the end of February 2015, which could be a positive catalyst for the company's H214/FY15 earnings since the timing gives the dealers some leeway in more flexible allocation, in our view.

Figure 5: BMW 3 2.0T retail pricing trend




Source: Company data, UBS estimates

Figure 6: BMW 525 2.0T pricing trend




Source: Company data, UBS estimates

Figure 7: BMW 7 3L retail pricing trend



Source: Company data, UBS estimates


Figure 8: BMW X5 retail pricing trend



Source: Company data, UBS estimates

Meanwhile, we have observed a weakening import volume trend over the past few months. According to the latest figures from the government, the import volume of motor vehicles and chassis (mainly premium and luxury cars) recorded YoY declines of 31% and 9% in February and January 2015, respectively. We note that inventory pressure from the imported cars was a major reason for dealers' weak profitability in H214, which eventually led to the disputes between dealers and OEMs. We believe OEMs are now trying to control the supply of imported cars, which will result in better pricing and margins at the retailers. We have already observed improving pricing for major brands and models of imported cars, such as the BMW 7 Series, Land Rover SUVs, and so on.

Figure 9: Motor vehicle and Chassis import volume (unit) and growth (%)



Source: CEIC

Figure 10: Imported high-end sedan retail pricing trend





Figure 11: Imported luxury SUV retail pricing trend



Source: Company data, UBS estimates

Source: Company data, UBS estimates

Policy reform update

In our 2 January 2015 dealership sector report, 'If winter comes, can spring be far behind?', we mentioned that the regulators are at the final stage of revising the franchise law governing the auto distribution sector. The major revisions include: 1) extending the dealers' authorised operating period; 2) opening up the supply chain; and 3) prohibiting cars that have been registered in foreign countries from being sold in China. However, the government has yet to announce the franchise law reforms. We believe the delay is due to the opposition of and lobbying by the OEMs, many of which showed serious concern about the aftermath of the reforms, based on our channel checks. We believe that the potential benefits to dealers have not been fully appreciated by the capital market yet. We still expect the finalized version to be announced within 2015.

On 9 February 2015, parallel imports were officially launched in the Shanghai pilot free trade zone. Yongda was one of the dealers qualified to set up parallel import operations in the pilot free trade zone. Given the potential revision of prohibiting cars that have been registered in foreign countries from being sold in China, we believe the parallel import business could bring only a minimal impact to the company's existing margins and ASP, due to limited sales volume and the recent weakening import growth.

Earnings revisions

We lower our H214 earnings estimate by 14% due to the lower-than-expected sales margin for new luxury cars and higher expenses from the launch of new businesses in H214 (i.e. used car, finance leases, and general repairing business), leading to a 9.7% reduction in our 2014 full-year earnings forecast. We expect the 2014 full-year sales margin for new luxury cars to decline from 4.6% to 4.3%, leading to an overall gross margin forecast decline from 9.1% to 8.9%. Meanwhile, we assume a higher SG&A ratio, from 5.6% to 5.7%, and 12% higher finance costs to reflect the higher expenses from the new business launches.

We also reduce our 2015/16 earnings forecasts slightly, 6.6%/6.9%, as a result of the lower sales margin for new luxury cars, down from 4.5%/4.4% to 4.4%/4.2%, leading overall gross margins to decline from 9.3%/9.7% to 9.2%/9.6%. We still expect the sales margins for new cars to stabilise, but at a slightly lower level. Moreover, we also increase our 2015/16 finance cost assumptions by 12.3%/20.1% after considering the expansion of Yongda's finance lease businesses.

We maintain our sales volume, service throughput, and revenue forecasts during 2014-16. Meanwhile, we forecast 2014/15/16 fully-diluted EPS of Rmb0.41/Rmb0.49/Rmb0.62, down from Rmb0.46/Rmb0.53/Rmb0.67 after accounting for the 10.7% potential dilution impact from Rmb1bn convertible bond issue in July 2014.

Our earnings estimates are 4%/12%/12% lower than consensus 2014/15/16 consensus estimated earnings, which we believe are already conservative.

Figure 12: Major assumption changes (Rmb m)

	2013	2014E		201	5E	2016E		
		Old	New	Old	New	Old	New	
Sales volume	81,882	94,799	94,799	108,782	108,782	122,154	122,154	
Mid-high end	39,558	42,335	42,335	46,896	46,896	49,775	49,775	
Luxury	42,324	52,464	52,464	61,886	61,886	72,379	72,379	
Service throughput	952,237	1,052,304	1,052,305	1,216,088	1,216,088	1,385,430	1,385,430	
Mid-high end	537,619	582,199	582,199	632,225	632,225	679,702	679,702	
Luxury	414,617	470,105	470,105	583,863	583,863	705,728	705,728	
Revenue	26,097	30,482	30,481	34,689	34,690	38,829	38,829	
New car sales (mid-high)	4,851	5,036	5,036	5,411	5,411	5,571	5,571	
New car sales (luxury)	18,392	21,886	21,886	24,794	24,794	27,709	27,709	
After-sales services	2,587	3,214	3,214	4,034	4,034	4,965	4,965	
Rental	266	346	346	450	450	585	585	
Gross profit	53.4%	54.0%	55.1%	55.6%	56.3%	57.9%	58.5%	
Total gross profit	2,267	2,763	2,711	3,240	3,204	3,747	3,709	
New car sales (mid-high)	136	151	151	162	162	167	167	
New car sales (luxury)	831	997	945	1,117	1,081	1,207	1,169	
After sales businesses	1,210	1,493	1,493	1,803	1,803	2,169	2,169	
Rental	89	121	121	157	157	205	205	
Overall gross margin (RHS)	8.7%	9.1%	8.9%	9.3%	9.2%	9.7%	9.6%	
Total new car sales (RHS)	4.2%	4.3%	4.1%	4.2%	4.1%	4.1%	4.0%	
New car sales (mid-high, RHS)	2.8%	3.0%	3.0%	3.0%	3.0%	3.0%	3.0%	
New car sales (luxury, RHS)	4.5%	4.6%	4.3%	4.5%	4.4%	4.4%	4.2%	
After-sales services	46.8%	46.5%	46.5%	44.7%	44.7%	43.7%	43.7%	
Rental	33.5%	35.0%	35.0%	34.9%	35.0%	35.0%	35.0%	
SG&A	1,437	1,707	1,737	2,012	2,012	2,252	2,252	
OP	1,081	1,350	1,268	1,601	1,557	1,906	1,853	
Finance cost	239	300	336	331	372	292	351	
Net income	588	716	646	864	807	1,096	1,021	
SG&A/Revenue	5.5%	5.6%	5.7%	5.8%	5.8%	5.8%	5.8%	
OP margin	4.1%	4.4%	4.2%	4.6%	4.5%	4.9%	4.8%	
Finance cost/Revenue	0.9%	1.0%	1.1%	1.0%	1.1%	0.8%	0.9%	
Net margin	2.3%	2.3%	2.1%	2.5%	2.3%	2.8%	2.6%	

Source: Company data, UBS estimates

Figure 13: VCAM summary

Relative year		+1E	+2E	+3E	+4E	+5E	+6E	+7E	+8E	+9E	+10E
Fiscal year		2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E
EBIT		1,510	1,814	2,194	2,517	2,784	2,876	2,996	3,111	3,219	3,319
D&A*		466	544	629	722	824	1,106	1,204	1,310	1,423	1,544
Capex		(867)	(777)	(854)	(940)	(1,015)	(1,383)	(1,581)	(1,801)	(2,045)	(2,315)
Chg. in wkg. cap.		(562)	(773)	(711)	(1,412)	(542)	(2,200)	(1,367)	(1,522)	(1,690)	(1,872)
Tax (operating)		(381)	(457)	(552)	(632)	(699)	(719)	(749)	(778)	(805)	(830)
Other		(177)	(174)	(163)	(179)	(158)	(192)	(206)	(221)	(237)	(254)
Free Cash Flow		(11)	178	543	77	1,194	(511)	297	99	(135)	(408)
	growth		NM	205.1%	-85.9%	1457.5%	-142.8%	NM	-66.8%	-236.8%	NM

Valuation	
PV of explicit cash flow	2,230
PV of terminal value (yr. 15)	7,950
Enterprise Value	10,179
% terminal	78%
Associates & other	174
- Minority interests	345
Surplus cash**	3,576
- Debt***	5,718
Equity value	7,866
Shares outstanding [m]	1,574.3
Equity per share (HK\$/sh)	6.19
Cost of equity	10.1%
Dividend yield	5.0%
1-year Price Target (HK\$/sh)	6.51

Long Term Assumptions								
Relative year	<u>+10E</u>	<u>+15E</u>	<u>+25E</u>					
Sales growth	8.5%	6.5%	5.0%					
EBIT margin	4.3%	3.3%	3.3%					
Capex/sales	3.0%	3.0%	3.0%					
ROIC	10.0%	7.6%	7.1%					

Valuation-Implied Metrics								
Fiscal year	2015E	2016E	1-yr Fwd.					
EV / EBITDA	5.2x	4.3x	5.0x					
EV / EBIT	6.7x	5.6x	6.5x					
FCF Yield	NM	1.7%	0.2%					
P / E (PV)	10.2x	8.0x	9.7x					
P / E (Target)	10.7x	8.4x	10.2x					

WACC								
Risk free rate	4.34%							
ERP	5.0%							
Beta	1.16							
Debt / equity **	98.8%							
Marg. tax rate	25.0%							
Cost of equity	10.1%							
Cost of debt	6.7%							
WACC	9.5%							

Terminal Assumptions						
VCH (years)	15					
Impl. FCF gr.	8.8%					
Incr. ROIC	9.0%					
EV / EBITDA	4.9x					

Figures in Rmb m, unless noted otherwise.

Source: UBS-VCAM

^{*} Depreciation and non-goodwill amortization

 $^{^{\}star\star}$ The portion of cash not required to maintain operations

^{***} Assumes market value of equity and includes market value/seasonal adjustments for debt and debt-deemed obligations.

China Yongda Automobiles Services (3669.HK)

Income statement (Rmbm)	12/11	12/12	12/13	12/14E	% ch	12/15E	% ch	12/16E	12/17E	12/18E
Revenues	20,304	21,712	26,097	30,481	16.8	34,690	13.8	38,829	42,712	46,983
Gross profit	1,600	1,771	2,267	2,711	19.6	3,204	18.2	3,709	4,271	4,792
EBITDA (UBS) Depreciation & amortisation	1,040 (129)	1,063 (169)	1,271 (208)	1,634 (380)	28.6 82.7	1,976 (466)	20.9 22.8	2,358 (544)	2,823 (629)	3,240 (722)
EBIT (UBS)	911	893	1,064	1,255	18.0	1,510	20.4	1,814	2,194	2,517
Associates & investment income	1	14	1,004	1,233	0.0	1,510	0.0	1,614	2,194 10	10
Other non-operating income	0	0	0	0	-	0	-	0	0	0
Net interest	(171)	(225)	(221)	(323)	-46.0	(325)	-0.7	(312)	(349)	(393)
Exceptionals (incl goodwill)	` ó	` ó	` ó	Ò	_	Ó	_	` ó	Ò	Ó
Profit before tax	741	682	853	942	10.5	1,195	26.9	1,512	1,855	2,135
Tax	(178)	(166)	(211)	(236)	-11.9	(299)	-26.9	(378)	(464)	(534)
Profit after tax	563	516	642	707	10.0	896	26.9	1,134	1,392	1,601
Preference dividends and Minorities	(58)	(45)	(54)	(60)	-11.8	(90)	-49.3	(113)	(139)	(160)
Extraordinary items	0	0	0	0	-	0	-	0	0	0
Net earnings (local GAAP)	505	470	588	646	9.9	807	24.8	1,021	1,252	1,441
Net earnings (UBS)	505	470	588	646	9.9	807	24.8	1,021	1,252	1,441
Tax rate (%)	24.0	24.3	24.7	25.0	1.2	25.0	0.0	25.0	25.0	25.0
Per share (Rmb)	12/11	12/12	12/13	12/14E	% ch	12/15E	% ch	12/16E	12/17E	12/18E
EPS (UBS, diluted)	0.34	0.32	0.40	0.41	4.3	0.49	18.8	0.62	0.76	0.88
EPS (local GAAP, diluted)	0.34	0.32	0.40	0.41	4.3	0.49	18.8	0.62	0.76	0.88
EPS (UBS, basic)	0.34	0.32	0.40	0.44	9.9	0.55	24.8	0.69	0.85	0.97
Net DPS (Rmb)	0.28	0.10	0.12	0.13	9.2	0.16	24.8	0.21	0.25	0.29
Book value per share	1.07	2.07	2.31	2.62	13.2	3.00	14.6	3.48	4.08	4.76
Average shares (diluted)	1,480.00	1,480.00	1,480.02	1,559.14	5.3	1,638.26	5.1	1,638.26	1,638.26	1,638.26
Balance sheet (Rmbm)	12/11	12/12	12/13	12/14E	0/ ch	12/155	0/ sh	12/16E	12/17E	12/18E
Cash and equivalents	1,080	1,895	1,418	5,044	% ch 255.6	12/15E 4,238	% ch -16.0	1,464	1,950	1,965
Other current assets	5,629	6,069	8,037	7,306	-9.1	8,481	16.1	9,928	11,239	13,334
Total current assets	6,709	7,964	9,455	12,350	30.6	12,719	3.0	11,393	13,189	15,299
Net tangible fixed assets	1,089	1,503	2,228	2,773	24.4	3,184	14.8	3,426	3,661	3,887
Net intangible fixed assets	15	27	381	381	0.0	381	0.0	381	381	381
Investments / other assets	347	502	834	834	0.0	835	0.1	836	837	838
Total assets	8,159	9,996	12,898	16,338	26.7	17,119	4.8	16,035	18,067	20,405
Trade payables & other ST liabilities	4,044	3,055	4,040	3,264	-19.2	3,737	14.5	4,222	4,691	5,228
Short term debt	2,356	3,465	3,887	6,567	68.94	6,224	-5.22	4,995	5,534	6,158
Total current liabilities	6,400	6,520	7,928	9,832	24.0	9,962	1.3	9,217	10,225	11,386
Long term debt	21	157	1,201	2,225	85.2	2,220	-0.2	1,054	1,061	1,069
Other long term liabilities	0	0	78	78	0.0	78	0.0	78	78	78
Preferred shares	0	0	0	0	-	0	-	0	0	0
Total liabilities (incl pref shares)	6,421	6,677	9,207	12,134	31.8	12,260	1.0	10,349	11,365	12,534
Common s/h equity	1,579	3,063	3,424	3,877	13.2	4,441	14.6	5,156	6,033	7,041
Minority interests	159	256	267	327	22.5	417	27.4	531	670	830
Total liabilities & equity	8,159	9,996	12,898	16,338	26.7	17,119	4.8	16,035	18,067	20,405
Cash flow (Rmbm)	12/11	12/12	12/13	12/14E	% ch	12/15E	% ch	12/16E	12/17E	12/18E
Net income (before pref divs)	505	470	588	646	9.9	807	24.8	1,021	1,252	1,441
Depreciation & amortisation	129	169	208	380	82.7	466	22.8	544	629 (711)	722
Net change in working capital Other operating	(292) 277	(576) 93	(949) 222	36 373	- 67.6	(562) 405	8.5	(773) 415	(711) 478	(1,412) 543
Operating cash flow	618	157	70	1,435	NM	1,115	<i>-22.3</i>	1,207	1,648	1,294
Tangible capital expenditure	(451)	(741)	(912)	(914)	-0.2	(867)	5.2	(777)	(854)	(940)
Intangible capital expenditure	(4)	(12)	(249)	0	-	0	-	0	0	(3.0)
Net (acquisitions) / disposals	1	231	(160)	0	_	0	_	Ö	Ö	0
Other investing	(826)	(4)	(196)	(68)	_	(94)	_	(151)	(95)	(118)
Investing cash flow	(1,279)	(526)	(1,518)	(983)	<i>35.2</i>	(961)	2.2	(927)	(949)	(1,057)
Equity dividends paid	(415)	(141)	(178)	(194)	-9.2	(242)	-24.8	(306)	(376)	(432)
Share issues / (buybacks)	494	1,125	0	0	-	0	-	0	0	0
Other financing	324	(1,046)	(317)	(336)	-5.84	(372)	-10.63	(351)	(384)	(422)
Change in debt & pref shares	857	1,246	1,466	3,704	152.59	(347)		(2,396)	547	632
Financing cash flow	1,260	1,184	971	3,174	226.8	(961)	_	(3,053)	(214)	(222)
Cash flow inc/(dec) in cash	599	815	(477)	3,626	-	(807)	_	(2,773)	486	15
FX / non cash items	0	0	Ò	0		Ó		0	0	0
Balance sheet inc/(dec) in cash	599	815	(477)	3,626	-	(807)	_	(2,773)	486	15
Source: Company accounts, UBS estimates. (UBS)	metrics use report	ted figures which			rsts.					

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts.

China Yongda Automobiles Services (3669.HK)

Valuation (x)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
P/E (local GAAP, diluted)	-	17.9	15.2	8.1	6.9	5.5	4.5	3.9
P/E (UBS, diluted)	_	17.9	15.2	8.1	6.9	5.5	4.5	3.9
P/CÈPS ,	-	13.2	11.2	4.9	4.0	3.2	2.7	2.3
Equity FCF (UBS) yield %	-	(7.1)	(12.4)	10.4	4.9	8.5	15.8	7.0
Net dividend yield (%)	-	`1.Ź	2.0	3.9	4.8	6.1	7.5	8.6
P/BV x	-	2.8	2.6	1.3	1.1	1.0	0.8	0.7
EV/revenues (core)	-	0.4	0.4	0.2	0.2	0.2	0.1	0.2
EV/EBITDA (core)	-	8.8	7.7	3.7	3.1	2.6	2.2	3.3
EV/EBIT (core)	-	10.5	9.2	4.8	4.0	3.4	2.9	4.2
EV/OpFCF (core)	-	10.4	9.1	4.7	4.0	3.4	2.9	4.2
EV/op. invested capital	-	2.4	1.6	0.8	0.7	0.7	0.6	0.9
Enterprise value (Rmbm)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Market cap.	-	8,332	8,813	4,997	5,036	5,036	5,036	5,036
Net debt (cash)	828	828	828	828	828	828	828	4,954
Buy out of minorities	159	256	267	327	417	531	670	830
Pension provisions/other	0	0	0	0	0	0	0	0
Total enterprise value	-	9,417	9,908	6,153	6,281	6,395	6,534	10,820
Non core assets	(61)	(68)	(161)	(172)	(182)	(192)	(202)	(213)
Core enterprise value		9,348	9,747	5,981	6,099	6,203	6,331	10,607
Growth (%)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Revenue	35.2	6.9	20.2	16.8	13.8	11.9	10.0	10.0
EBITDA (UBS)	39.2	2.2	19.7	28.6	20.9	19.3	19.7	14.8
EBIT (UBS)	44.7	-1.9	19.1	18.0	20.4	20.1	20.9	14.7
EPS (UBS, diluted)	30.9	-6.8	25.1	4.3	18.8	26.5	22.7	15.1
Net DPS	NM	-66.2	26.3	9.2	24.8	26.5	22.7	15.1
Margins & Profitability (%)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Gross profit margin	7.9	8.2	8.7	8.9	9.2	9.6	10.0	10.2
EBITDA margin	5.1	4.9	4.9	5.4	5.7	6.1	6.6	6.9
EBIT margin	4.5	4.1	4.1	4.1	4.4	4.7	5.1	5.4
Net earnings (UBS) margin	2.5	2.2	2.3	2.1	2.3	2.6	2.9	3.1
ROIC (EBIT)	35.0	22.5	17.5	16.8	18.1	19.1	20.7	20.9
ROIC post tax	26.6	16.9	13.1	12.5	13.6	14.3	15.5	15.7
ROE (UBS)	37.5	20.3	18.1	17.7	19.4	21.3	22.4	22.0
Capital structure & Coverage (x)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Net debt / EBITDA	1.2	1.6	2.9	2.3	2.1	1.9	1.6	1.6
Net debt / total equity %	74.6	52.0	99.4	89.1	86.6	80.6	69.3	66.9
Net debt / (net debt + total equity) %	42.7	34.2	49.9	47.1	46.4	44.6	40.9	40.1
Net debt/EV %	-	18.5	37.7	62.7	69.0	73.9	73.4	49.6
Capex / depreciation %	NM	NM	NM	NM	190.0	145.4	137.9	131.7
Capex / revenue %	2.2	3.4	3.5	3.0	2.5	2.0	2.0	2.0
EBIT / net interest	5.3	4.0	4.8	3.9	4.6	5.8	6.3	6.4 3.3
Dividend cover (UBS) Div. payout ratio (UBS) %	1.2 82.3	3.3 29.9	3.3 30.2	3.3 30.0	3.3 30.0	3.3 30.0	3.3 30.0	30.0
Div. payout fatio (OB3) 76	02.3	29.9	30.2	30.0	30.0	30.0	30.0	30.0
Revenues by division (Rmbm)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Others	20,304	21,712	26,097	30,481	34,690	38,829	42,712	46,983
Total	20,304	21,712	26,097	30,481	34,690	38,829	42,712	46,983
EBIT (UBS) by division (Rmbm)	12/11	12/12	12/13	12/14E	12/15E	12/16E	12/17E	12/18E
Others	911	893	1,064	1,255	1,510	1,814	2,194	2,517
Total	911	893	1,064	1,255	1,510	1,814	2,194	2,517
Source: Company accounts, UBS estimates, (UBS) metrics					.,5 10	.,017	=,134	-,517

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts.

Forecast returns

Forecast price appreciation	+54.0%
Forecast dividend yield	4.8%
Forecast stock return	+58.8%
Market return assumption	9.3%
Forecast excess return	+49.5%

Statement of Risk

We believe the main risks to the industry include: 1) a slowdown in car sales, especially luxury cars; 2) a decline in new car sales margins; and 3) a slowdown in M&A activity.

Required Disclosures

This report has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	47%	37%
Neutral	FSR is between -6% and 6% of the MRA.	42%	32%
Sell	FSR is > 6% below the MRA.	11%	21%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	less than 1%	less than 1%

Source: UBS. Rating allocations are as of 31 December 2014.

1:Percentage of companies under coverage globally within the 12-month rating category. 2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months. 3:Percentage of companies under coverage globally within the Short-Term rating category. 4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected nearterm (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS AG Hong Kong Branch: Ming Xu; Yankun Hou; Mark Leung.

Company Disclosures

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
China Yongda Automobiles Services ^{2, 4}	3669.HK	Suspended	N/A	HK\$4.22	12 Mar 2015


Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

- 2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
- 4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

China Yongda Automobiles Services (HK\$)



Source: UBS; as of 12 Mar 2015

Global Disclaimer

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is or a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ('the Information'), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. Poland: Distributed by UBS Limited (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. Russia: Prepared and distributed by UBS Bank (OOO). Switzerland: Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Limited and distributed by UBS Limited and UBS Italia Sim S.p.A. UBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. Saudi Arabia: This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **Dubai:** The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United United States: Distributed to ÚS persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. Brazil: Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities. **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 016/09/2014 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd., be author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. Australia: Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia (Holder of Australian Financial Services License No. 231098). Clients of UBS Wealth Management Australia Ltd: Distributed by UBS Wealth Management Australia Ltd (Holder of Australian Financial Services Licence No. 231127). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg. **New Zealand:** Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: Pte. Ltd., Seoul Branch. CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. India: Prepared by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment): INB230951431, INB230 Segment) INB010951437.

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2015. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

